drugset / Trial / NCT00637221
Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome
RandomizedFactorialOpen-labelTreatment
Summary
This is an open label exploratory study to investigate the safety and effects of a single dose of NPL-2009(50 mg - 150 mg) on Prepulse Inhibition (PPI) Tests and Continuous Performance Tasks (CPT) in adults with Fragile X Syndrome
Timeline
- Start
- 2008-03
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FENOBAM ANHYDROUS | Small molecule | 50 mg | — |
| Subject | FENOBAM ANHYDROUS | Small molecule | 100 mg | — |
| Subject | FENOBAM ANHYDROUS | Small molecule | 150 mg | — |